Evidence map›Paper›PMID 30274301›Full record

ArticleInternational journal of molecular sciences2018

Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with

Aya Sugyo, Atsushi B Tsuji, Hitomi Sudo, Mitsuru Koizumi, Yoshinori Ukai, Gene Kurosawa, Yoshikazu Kurosawa, Tsuneo Saga, Tatsuya Higashi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Therapeutic anti-CD147 antibody sensitizes cells to chemoradiotherapyAmerican journal of translational research · 2019
    Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Aya SugyoDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology (QST-NIRS), 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan. sugyo.aya@qst.go.jp.
Atsushi B TsujiDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology (QST-NIRS), 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan. tsuji.atsushi@qst.go.jp.ORCID 0000-0003-2726-288X
Hitomi SudoDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology (QST-NIRS), 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan. sudo.hitomi@qst.go.jp.
Mitsuru KoizumiDepartment of Nuclear Medicine, Cancer Institute Hospital, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan. mitsuru@jfcr.or.jp.
Yoshinori UkaiResearch and Development Division, Perseus Proteomics Inc., 4-7-6 Komaba, Meguro-ku, Tokyo 153-0041, Japan. yukai@fujita-hu.ac.jp.ORCID 0000-0001-7661-7777
Gene KurosawaInnovation Center for Advanced Medicine, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan. gene@fujita-hu.ac.jp.
Yoshikazu KurosawaInnovation Center for Advanced Medicine, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan. kurosawa@fujita-hu.ac.jp.
Tsuneo SagaDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology (QST-NIRS), 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan. saga@kuhp.kyoto-u.ac.jp.
Tatsuya HigashiDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology (QST-NIRS), 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan. higashi.tatsuya@qst.go.jp.
National Institutes for Quantum Science and Technology · JPFujita Health University Hospital · JPThe Cancer Institute Hospital · JP

Funding

Ministry of Education, Culture, Sports, Science and Technology 25861140, 17K10497, and 18H02774
6 · The paper itself

Abstract

The poor prognosis of pancreatic cancer requires the development of more effective therapy. CD147 expresses in pancreatic cancer with high incidence and has a crucial role in invasion and metastasis. We developed a fully human monoclonal antibody (059-053) with high affinity for CD147. Here we evaluated the efficacy of combined treatment using radioimmunotherapy (RIT) with

Indexed as

AnimalsAntibodies, MonoclonalBasiginCell Line, TumorDeoxycytidineDisease Models, AnimalGemcitabineHumansImmunohistochemistryMaleMatrix Metalloproteinase 2Matrix Metalloproteinase 9MiceMice, Inbred BALB CPancreatic NeoplasmsRadioimmunotherapyAntibodies, MonoclonalBasiginDeoxycytidineGemcitabineMatrix Metalloproteinase 2Matrix Metalloproteinase 9Yttrium-90Yttrium Radioisotopescombination therapyextracellular matrix metalloproteinase inducergemcitabinepancreatic cancerradioimmunotherapy

Identifiers

PMID30274301
PMCPMC6213240
OpenAlexW2894129104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.